|
|
|
|
|
|
|
|
129th MAINE LEGISLATURE |
|
|
LD 1162 |
|
LR 786(03) |
|
|
|
An Act To Further
Expand Drug Price Transparency |
|
Fiscal Note for
Bill as Engrossed with:
C "A" (S-252) |
|
Committee: Health Coverage, Insurance and
Financial Services |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fiscal Note |
|
|
|
|
|
|
|
Minor cost increase - General Fund
Minor revenue increase - General Fund
Minor revenue increase - Other Special Revenue Funds |
|
|
|
|
|
|
|
| Correctional and
Judicial Impact Statements |
|
|
|
|
|
The additional
workload associated with the minimal number of new cases filed in the court
system does not require additional funding at this time.
The collection of additional fine revenue will increase General Fund and
dedicated revenue by minor amounts. |
|
|
|
|
|
|
|
| Fiscal Detail
and Notes |
|
|
|
|
|
|
The bill requires
prescription drug manufacturers to report to the Maine Health Data
Organization (MHDO) on prescription drug information under certain situations
or when requested by MHDO and requires MHDO to annually produce and post a
report of this information on its website. Any costs to MHDO to carry out
these provisions are expected to be minor and can be absorbed within budgeted
resources. The bill also authorizes MHDO to collect an annual assessment on
drug manufacturers of $500. Additional revenues collected from these
assessments are expected to increase Other Special Revenue Fund revenues by
minor amounts. |
|
|
|
|
|
|
|